Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year

Group 1 - Investing in clinical-stage biotechs offers significant upside potential but comes with above-average risk, making it essential to choose wisely to avoid losses [1] - Point72 Asset Management, led by billionaire Steve Cohen, has invested in Abivax, a France-based clinical-stage biotech, which has seen its shares increase by over 1,600% in the past year [2][4] - Point72's investment strategy involves maintaining a diversified portfolio, with Abivax accounting for only 0.43% of its holdings, indicating a cautious approach to high-risk investments [3][4] Group 2 - Abivax's leading candidate, obefazimod, is being developed as a treatment for ulcerative colitis and has shown promising results in a phase 3 clinical trial, with 47% of participants having inadequate responses to prior therapies [6] - The investment model suggested includes buying a small number of shares in promising biotechs before significant clinical progress and taking profits as the stock price rises, while remaining invested for potential acquisition or approval of pipeline candidates [5]